

Market-Derived Patent Data: What Data is Important and How Does It Impact Value?

Mike Pellegrino

President, Pellegrino & Associates, LLC

mike@pellegrinoandassociates.com

About Mike Pellegrino

- **President of Pellegrino & Associates**
 - 16 year old consulting firm, >400 projects, ~300 clients
 - Frequent speaker/author around world on valuation topics
- **Provide strategic IP consulting, valuation, and damages analysis to companies large and small around world**
 - Intel, IBM, State Farm, Yum! Brands, Uber, Ericsson, Office Depot, ZTE, GE, Avaya, Lockheed Martin, Biomet, ABB, Ingersoll-Rand, Elanco, Bissell, Rolls-Royce, Sony, Con-Ed, TeleTech, AM General, Celanese, etc.
- **Recovering professional software developer**
 - Developed massive research data sets for patent analytics
 - ~10-year record in patent analytics analysis and publishing


Some Major Headlines

- **“Google Buys 1,023 IBM Patents to Bolster Defense of Android”**
- **“Facebook Is Said to Buy 750 IBM Patents to Boost Defense”**
- **“Facebook Buys AOL Patents From Microsoft for \$550 Million”**
- **“AOL Announces Close of \$1.056 Billion Patent Transaction with Microsoft”**
- **“Intel to buy InterDigital patents for \$375 million”**
- **“Acacia Subsidiary Acquires Patents Related to Cellular HSPA and LTE Technology from a Major Corporation”**
- **Why is all of this occurring?**

- **Economic justification**
 - Authorized right to exclude others
 - Economic construct enables abnormal profits via price skimming
 - Right patent is worth more than most companies!
- **Democratizing economic instrument**
 - Larry Page is long way from modest Michigan upbringing
 - Started on the back of a patent from 1997
- **Defensive posturing drives significant recent patent activity**
 - Microsoft received 86 patent grants in 2000
 - Now within the top 10 recipients in any given week for new U.S. patent grants


Ignorance is **NOT** Bliss

- What happens when a patent-centric consumer-based business stops investing in IP:



- This happens in pharmaceuticals too:

Patent Grants and Stock Price



This is Big Business

- **>94% of all patents assigned at time of award to companies**
 - Top 300 patent holders own >half of the issued patents
- **Lots of money at stake**
 - At \$10,000 per patent, prosecution fees top \$4 billion per year
 - Does not include internal staff time (e.g., patent review committees), consultants, etc.
- **>2,500 patent lawsuits enter court system each year**
 - >\$7.5 billion dedicated to patent litigation, damages, productivity losses, etc.
- **This spend is a relative pittance compared to the economic value creation attributable to patents**
 - The same holds true for patent lawsuits

Generalized Hot Development Areas

Main U.S. Patent Class	Patent Count	Gov't Funded	Abandonment Rate
438 - Semiconductor Device Manufacturing: Process	65,983	598	11.02%
257 - Active Solid-State Devices	60,801	665	8.97%
370 - Multiplex Communications	54,525	303	6.75%
514 - Drug, Bio-Affecting And Body Treating Compositions	50,056	2,780	27.25%
455 – Telecommunications	43,444	115	7.87%
435 - Chemistry: Molecular Biology And Microbiology	41,890	4,424	22.54%
345 - Computer Graphics Processing And Selective Visual Display Systems	35,871	116	10.56%
709 - Electrical Computers And Digital Processing Systems: Multicomputer Data Transferring	34,399	155	6.46%
424 - Drug, Bio-Affecting And Body Treating Compositions	32,943	1,914	19.90%
428 - Stock Material Or Miscellaneous Articles	32,546	467	20.48%

- **Pain:** Comps do not work well with patents
 - Not selling commodities
 - Difficult to identify prospects
 - Difficult to gauge a good deal
 - Remarkable amount of information asymmetry in IP by design
- **Pain:** Individual patent analysis is impractical
 - Expensive
 - Takes time
 - Does not scale well
 - Dependent on analyst quality
- **Need:** Must derive credible answers on large portfolios
 - Oftentimes in hours


- **Facts:** There are millions patents in force
 - About 6,500 new patents issue each week, ~340K per year
 - About 7,500 applications publish each week, ~380K per year
 - >20,000 assignments publish each week, ~1M per year
 - Transactions, withdrawals, abandonments and expirations change daily picture
- **Problem:** The dataset is huge
 - USPTO dataset is ~100TB
 - USPTO publishes >130GB of compressed data each week
 - Data spread among various different, discrete data sources
 - Compounds with international data sources
- **Pain:** Smart people make suboptimal IP decisions constantly
 - How does one reasonably consider all of this information?

Data-Derived Patent Metrics


- **Thesis:** Underlying behavior has an economic basis, driving business decisions
 - **Result:** People's behavior informs on patent strategy
 - Whether they want it to or not
 - **Impact:** Narrows the focus of where to expend scarce resources
 - Increases operating margin of consulting practices
- **Example:** Apple filed several reissues on patent #6,956,564
 - Concept originated in 1998 in England
 - Apple bought patent from British Telecom in 2007
 - Underlying technology was defining feature of original iPhone
 - Describes device that changes display view tied to accelerometer

Apple Example

- Original 1998 British Telecom preferred embodiment



- How Apple applied the patent in 2007



- **Patent data is not normally distributed**
 - Depends heavily on tail analysis in many forms
- **Behavior embedded in the public information**
 - Just need to know where to look (e.g., the tails)
 - Sophisticated strategists cannot hide behavior
 - Especially in specific technology areas of interest
- **Behavior informs on many different levels**
 - Patent relevance
 - Mortality analysis
 - Market inspiration
 - Prosecution strategy
 - Operational efficiency
 - Technology importance

Why Consider Macro Patent Data?

- Key innovations typically rely on patents
- Such data is publicly available
- Patent data is authoritative
 - Easy to use in court
 - Published by U.S. government
 - Generally federated by college-educated workforce
- Statistical analysis of trends in data informs market on variety of levels
- **Impact:** Insights open doors to new influencers on patent value (both positive and negative)

- **Today's discussion focuses on variety of USPTO data sources**
 - Patent grants – 6.9 million
 - Patent applications – 5.6 million
 - Assignments – 10 million
 - Maintenance fee events – 16.4 million
 - PAIR dockets – 9.3 million (5.6 million with full image file wrappers)
 - PRPS dockets – ~93,300
 - PTAB E2E dockets – ~11,300
 - Ex parte reexaminations – > 8,700
 - Inter partes reexaminations – >1,700

- **Data sources have limitations**
 - Errors in data that the USPTO receives
 - Some errors are trivial (i.e., misspelled name)
 - Some errors are more serious (wrong dates on patents)
 - Much of the data is impossible to change
 - Patents are legal documents and require costly legal documents to make edits or corrections
- **Each data source tracks data differently**
 - Mapping must occur, which is a noisy process
- **Such noise does not alter any conclusions materially**

- **Hundreds of tracking signals**
 - Way too many to discuss today
- **Several major ones**
 - Grant activity
 - Application activity
 - Application/grant (A/G) ratio
 - Patent priority
 - Portfolio composition
 - Provisional strategy
 - Prosecution progeny
 - Prosecution difficulty
 - Transaction activity
 - Maintenance activity

- Rate of change in grants indicates current/historic market significance
- For example:
 - Few patents in button making
 - Many patents in multiplex communications
 - Grant activity has increased over time
- **Conclusion:**
 - Patents for multiplex communications are of greater interest to the market than they are for button making
 - Button making patents are likely worth less and/or there is no buyer

- **Location of art indicates market significance**
 - Perform search for “diabetes”
 - Most patents are in chemical compound and biotech art classes
 - Little possible relevance if end device is a diagnostic for measuring glucose levels
 - In such a situation, most diabetes patents bring little relevance to analysis
 - Data informs us that market is more interested in treating disease via drugs versus devices
- **Impact:** Lack of data can be helpful in opining on patent value


- Patent applications are leading indicator to patent grants
- Rate of change in application indicates current/future market significance
 - For example:
 - Many new patents in soft tissue repair for spinal discs
 - Conclusion:
 - Possible growth market for an orthopedic company
- Like patent grant activity, location of art indicates market significance

- **A/G ratio provides evidence of market significance over time**
 - Total patent applications / total patent grants
- **Interpretation**
 - <1 : Market interest is waning as new filings lag grants
 - $=1$: Market's interest is stable and maintained as new filings keep up with patent grants
 - >1 : Market interest is growing as new filings exceed grants
- **Impact:** A company's A/G ratio can tell you whether their pace of innovation is slowing or not.
 - Same holds true for broader market


- Patents have an associated priority
 - Think of patent priority like a place in line
 - Patent priority is based on a date
 - That date is the point where invention novelty evaluation begins
 - Patents with earlier priority dates are closer to line front
 - Patents with earlier priority dates might exhibit a greater degree of novelty and be more foundational in nature
 - Patents with later priority dates might exhibit a lesser degree of novelty and be more incremental in nature
- **Impact:** Foundational patents generally worth more

Patent Priority Profile


General Patent Priority



- Patents with earlier priority dates may be more valuable
- **Impact:** Less impeaching art = less invalidity risk



- Priority date of patent Apple bought from British Telecom
 - Apple sued HTC in 2011 with this patent




- **Thesis:** Patent types matter
 - Parent, continuations, divisionals, CIPs, etc.
 - Companies play games with patent types
- **Heavy focus on continuations**
 - Relatively inexpensive bulking up strategy
 - Makes portfolio look large
 - Reality is narrow scope
 - Oftentimes waste of money


- **Example:**
 - Only 18% of Huawei's portfolio are parent assets
 - Most are continuations
 - Deep coverage in narrow footprint
 - Less valuable than Qualcomm, Ericsson Nokia, etc.
 - Public record regarding royalty payments confirms

Portfolio Composition

Huawei



Nokia



- **Metric highlights breadth of portfolio**
 - Ratio of parent assets to total portfolio size
 - Quickly highlights which companies are bulking portfolios
 - Range: $0 < \text{Integration Ratio} < 1$
 - Ratios closer to 1 are horizontally aligned
 - Longer economic lives
 - Generally broader in scope
 - Generally more valuable all else the same
 - Ratios closer to 0 are vertically aligned
 - Shorter economic lives
 - Deeper, but narrower scope
 - Generally less valuable all else the same

Integration Ratio

Assignee	Grants	Terminal disclaimer	Horizontal integration ratio	Parent patents
International Business Machines Corporation	8,861	37%	56%	4,992
Samsung Electronics Co, Ltd	6,840	11%	82%	5,585
Canon Kabushiki Kaisha	3,331	4%	84%	2,809
LG Electronics Inc	3,086	20%	73%	2,265
Intel Corporation	3,063	17%	71%	2,171
Google, LLC	2,838	23%	61%	1,725
QUALCOMM Incorporated	2,646	9%	84%	2,219
Apple Inc	2,593	15%	58%	1,517
Microsoft Technology Licensing, LLC	2,409	22%	69%	1,663
Samsung Display Co, Ltd	2,306	5%	88%	2,036
Toyota Jidosha Kabushiki Kaisha	2,120	2%	96%	2,037
Amazon Technologies, Inc	1,985	15%	76%	1,508
Ford Global Technologies, LLC	1,949	5%	86%	1,678
Sony Corporation	1,803	20%	58%	1,054
General Electric Company	1,605	6%	86%	1,383
Taiwan Semiconductor Manufacturing Company, Ltd	1,558	11%	50%	777


- **Thesis:** Provisional applications are leading innovation indicator
 - Many grants have multiple associated provisional applications
 - The volume and frequency of provisional applications highlight key focus areas
 - Large patent families tend to have many associated provisional applications
 - Provisional application change rates important indicator to future portfolio growth

- **Example #1:**

- Google acquires patent portfolio from Exbiblio B.V. in 2011
- Addresses text capture from rendered documents
 - Important capability for search engines
- Parent patent #7,707,039
 - Priority dates back to 2004
 - > 100 provisional applications
 - > 80 progeny today
- Google still prosecuting patents under this estate in 2019
 - Most recent published application filed September 17, 2018

- **Example #2:**

- Microsoft files large number of provisional applications in 2011-2012
- Address augmented reality inventions
- Coincident to Google activities based on “Google Glass” search trends
 - Microsoft appears to be following Google in this area



- **Thesis:** Many progeny = significant patent estate
 - There is business reason for depth of filings
 - Seeking coverage of many variations of inventions
 - Can highlight remarkable value risk in the portfolio

- **Example :**
 - FitBit has about 340 granted patents
 - Owns U.S. patent #9,167,991
 - Addresses portable devices that monitor caloric burn
 - Parent asset has 108 progeny
 - Among deepest progeny trees in entire USPTO data set
 - 32% of FitBit portfolio emerges from '991 original specification
 - FitBit has remarkably narrow coverage in only one inventive area
 - Risky proposition for a consumer electronics company
- **This issue is not unique among companies**
 - E.g., Huawei, Dolby, Digimarc, etc.

- Stock market finally caught up with FitBit's inventive reality
 - Same story at GoPro, though not as extreme

Fitbit Inc.



GoPro Inc.



- **Thesis:** Companies invest significant sums to acquire patents important to them
 - ~66% of patents sail through USPTO
 - Zero or one rejection
 - Rejections are expensive to address
 - Generally \$1,500-\$2,500 each
 - Not including requests for continued examination (RCEs) or appeals

- **Example:**

- Procter & Gamble U.S. patent #9,585,827

- Addresses dental erosion (i.e., tooth decay) using sodium hexametaphosphate
- Earliest effective filing date: January 21, 2000
- 11 non-final rejections, 12 final rejections, 9 RCEs, 6,255 days pendency (**17 years!**)
- Patent issues March 7, 2017, four years before it expires


- There is a business reason that explains this behavior

- Essential ingredient in Crest Pro-Health toothpaste


- Sodium hexametaphosphate helps fight stains and tartar buildup

Prosecution Difficulty


Agent Rejection Histogram




Examiner Rejection Histogram



Assignee Rejection Histogram



Subclass Rejection Histogram




- **Patent citations are references to other granted patents or published patent applications**
 - Similar to references in academic publications
 - Have relevance to the patent of interest
- **Much interest exists in using citations to indicate patent quality value**
 - Some academic research indicates that companies that have high degrees of citation to their patents have greater market values

- A high degree of citations is indicative of market significance
 - That intelligence can be valuable
 - Helps identify possible licensees and acquirers
 - Provides basis for inspiration to other inventors in the market
- There is tenuous direct connection between patent citations and patent quality or patent value
 - Market players like metric though
- **Impact:** Highly cited patents generate greater market interest

- **Pros**
 - Cheap data source
 - Easy to use data source
 - Lots of published research
 - Not necessarily “good” research
 - Some mixed use precedent in court
- **Cons**
 - 1980’s thinking
 - Weak and imprecise correlations
 - Generally poor and abused metric

Patent Transaction Activity

- **Thesis:** Companies actively transact for valuable patents
- **Impact:** Art classes with assignments = market interest/value



- **Transactions may comprise:**
 - Mergers
 - Assignments
 - Security interests (e.g., corporate financing)
 - And other rights conveyances...
- **Searches that yield many transactions may indicate:**
 - List of possible licensees or buyers for given technology
 - Active interest and market relevance in related technologies
- **Quality of companies buying patents may provide significant credibility boost to patented concept**
 - NPE acquisitions highlight relevant downstream risk areas

- **Patents are enforceable only when maintained**
 - If patent owner does not maintain patent, then no enforcement lever exists
 - Patent maintenance is expensive
 - Gets incrementally more expensive at each maintenance event
 - Large companies can spend tens of millions of dollars per year on maintenance fees
- **Strong relationship between valuable patents and maintained patents**
 - Foolish to let a patent lapse that is generating value
- **Patent maintenance rates can inform on economic lives of assets**
 - Communications companies maintain >98% of their patents
 - Large pharmaceutical companies **abandon** >70% of their patents

- **IBM is late on > 70% of maintenance fees in 2012 timeframe**
 - > 10,000 late payments, paid about \$1.6 million in late charges
 - Quite surprising given IBM's sophistication
- **Answer: Creative financing:**
 - IBM defers >\$40 million in expense
 - Assumes average cost of \$4,000 per payment
 - **8% annualized financing cost**
 - Pretty expensive debt for IBM, who borrows at lower amounts
 - **However, constitutes off-balance sheet financing arrangement**
 - Hidden from relatively unsophisticated auditors, allows IBM to defer expenses
 - **1 billion shares in play**
 - Enables earnings management to tune of a penny or two per share

What Do We Do With The Data?

- **Patent valuation does not start or end on statistical analysis**
 - No direct connection in absolute terms (e.g., dollars)
 - Statistics inform on a variety of factors important to valuation process
- **New insights and value influencers may include:**
 - Litigation value
 - Licensee analysis
 - Economic life of the patent
 - Exit analysis (i.e., possible buyers)
 - Competitors at the company level
 - Competitors at the product or service level
 - Market interest in the technology
 - This may impact forecast growth rates